Edition:
United Kingdom

Cipla Ltd (CIPL.NS)

CIPL.NS on National Stock Exchange of India

520.70INR
10:29am GMT
Change (% chg)

Rs-7.55 (-1.43%)
Prev Close
Rs528.25
Open
Rs528.00
Day's High
Rs529.85
Day's Low
Rs518.65
Volume
1,707,971
Avg. Vol
2,786,030
52-wk High
Rs678.45
52-wk Low
Rs507.20

Latest Key Developments (Source: Significant Developments)

Cipla Gets Final Approval For Generic Version Of Roche's Valcyte
Monday, 12 Nov 2018 

Nov 12 (Reuters) - Cipla Ltd ::CIPLA RECEIVES FINAL APPROVAL FOR GENERIC VERSION OF ROCHE'S VALCYTE (VALGANCICLOVIR TABLETS 450MG).  Full Article

Cipla Sees Multiple Headwinds Impact Reported Performance In H2
Monday, 5 Nov 2018 

Nov 5 (Reuters) - Cipla Ltd ::"AS WE ENTER THE SECOND HALF OF THIS FISCAL, MULTIPLE HEADWINDS ARE LIKELY TO IMPACT OUR REPORTED PERFORMANCE".  Full Article

Cipla Gets Final Nod For Generic Version Of Aralez Pharmaceuticals' Toprol Xl ER Tablets
Monday, 29 Oct 2018 

Oct 29 (Reuters) - Cipla Ltd ::RECEIVES FINAL APPROVAL FOR GENERIC VERSION OF ARALEZ PHARMACEUTICALS, INC.'S TOPROL XL ER TABLETS 50MG, 100MG, 200MG..  Full Article

Cipla Gets Final Approval For Generic Reyataz
Friday, 10 Aug 2018 

Aug 10 (Reuters) - Cipla Ltd ::CIPLA RECEIVES FINAL APPROVAL FOR GENERIC REYATAZ.DRUG INDICATED FOR USE IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR TREATMENT OF HIV-1 INFECTION.  Full Article

U.S. FDA Assigns Voluntary Action Status To Cipla's Indore Unit - ET Now, Citing Cogencis
Friday, 6 Jul 2018 

July 6 (Reuters) - :U.S. FDA ASSIGNS VOLUNTARY ACTION STATUS TO CIPLA LTD'S INDORE UNIT - ET NOW, CITING COGENCIS.  Full Article

Cipla Gets Final Approval For Generic Depo-Testosterone From U.S. FDA
Thursday, 21 Jun 2018 

June 21 (Reuters) - Cipla Ltd ::SAYS CO RECEIVED FINAL APPROVAL FOR ANDA FOR TESTOSTERONE CYPIONATE INJECTION 100MG/ML AND 200MG/ML FROM U.S. FDA.  Full Article

India's Cipla Gets Final Nod From U.S FDA For Efavirenz Tablets
Tuesday, 19 Jun 2018 

June 19 (Reuters) - Cipla Ltd ::SAYS GOT FINAL APPROVAL FOR ITS ABBREVIATED NEW DRUG APPLICATION (ANDA) FOR EFAVIRENZ TABLETS 600MG FROM USFDA.DRUG INDICATED IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTION.  Full Article

India's Cipla Ltd Posts March Qtr Consol Profit
Tuesday, 22 May 2018 

May 22 (Reuters) - Cipla Ltd ::MARCH QUARTER CONSOL NET PROFIT 1.79 BILLION RUPEES VERSUS LOSS OF 617.9 MILLION RUPEES LAST YEAR.CONSENSUS FORECAST FOR MARCH QUARTER CONSOL NET PROFIT WAS 3.57 BILLION RUPEES.MARCH QUARTER CONSOL NET SALES 34.96 BILLION RUPEES VERSUS 34.87 BILLION RUPEES LAST YEAR.RECOMMENDED DIVIDEND OF 3 RUPEES PER SHARE.SAYS MARCH QUARTER CONSOL EXCEPTIONAL ITEM OF 775.2 MILLION RUPEES.  Full Article

Mannkind And Cipla Enter An Exclusive Marketing And Distribution Agreement For Afrezza® In India
Wednesday, 9 May 2018 

May 9 (Reuters) - Cipla Ltd ::MANNKIND AND CIPLA ENTER AN EXCLUSIVE MARKETING AND DISTRIBUTION AGREEMENT FOR AFREZZA® IN INDIA.MANNKIND - UNDER TERMS OF AGREEMENT, CIPLA WILL BE RESPONSIBLE FOR OBTAINING REGULATORY APPROVALS TO DISTRIBUTE AFREZZA IN INDIA.MANNKIND CORP - EXCLUSIVE MARKETING & DISTRIBUTION DEAL FOR AFREZZA IN INDIA WITH CIPLA LTD.MANNKIND CORP - CIPLA WILL ALSO BE RESPONSIBLE FOR ALL MARKETING AND SALES ACTIVITIES OF AFREZZA IN INDIA.MANNKIND CORP - MANNKIND IS RESPONSIBLE FOR SUPPLYING AFREZZA TO CIPLA.MANNKIND CORP - MANNKIND WILL RECEIVE A $2.2 MILLION UPFRONT PAYMENT FROM CIPLA WITHIN 30 DAYS OF ENTERING AGREEMENT.  Full Article

India's Cipla Gets Final Nod For Generic Vazculep, Others
Wednesday, 2 May 2018 

May 2 (Reuters) - Cipla Ltd ::GETS FINAL NOD FOR GENERIC VAZCULEP, GENERIC PHENYLEPHRINE HYDROCHLORIDE INJECTION USP, 10 MG/ML SINGLE-DOSE VIAL, GENERIC AROMASIN.PRODUCTS ARE MANUFACTURED AT CO'S GOA PLANT.  Full Article

UPDATE 1-India's Cipla warns of headwinds in second half after Q2 profit miss

Nov 5 Cipla Ltd, India's second-largest drugmaker by market capitalisation, warned on Monday of "multiple headwinds" in the second half of the financial year after its quarterly profit fell short of analysts' estimates.